News | Proton Therapy | October 27, 2015

IBA Announces Upgrades to Penn Medicine Proton Therapy Center Equipment

New advances include cone beam CT, pencil beam scanning technology

Penn Medicine, IBA upgrades, Roberts Proton Therapy Center, PBS, CBCT

October 27, 2015 — IBA announced that longtime customer and research partner Penn Medicine has upgraded the equipment of its Roberts Proton Therapy Center with the latest innovations in proton therapy treatment. This upgrade to the newest technologies will allow Penn Medicine’s staff to continue to offer top-level proton radiation therapy services to an increasing number of patients and to further advance the clinical application of proton therapy.

Penn Medicine treated its first proton patient in March 2010. Research collaborations with IBA are extensive, with Penn Medicine contributing to the research on pencil beam scanning (PBS) protocols and cone beam computed tomography (CBCT), among others. Penn Medicine’s proton therapy facility and experts also play a key role in IBA’s training program, sharing knowledge and experience to contribute to the education of the entire proton therapy community.

Recent acquisitions by the Roberts Proton Therapy Center include:

  • Having taken part in the development and optimization of IBA’s CBCT, Penn Medicine has opted to purchase this image guidance tool, which ensures increased accuracy in patient positioning and brings the center one step closer to adaptive proton therapy treatment;
  • Penn Medicine will replace one of its universal nozzles to a dedicated PBS nozzle. This brings Penn Medicine to a total of four PBS treatment rooms, with one double scattering treatment room remaining. It will allow Penn clinicians to offer the most accurate delivery of proton therapy currently available to a larger number of patients, while maintaining the advantage double scattering provides when treating moving targets. This adapted configuration provides Penn Medicine with the option to cover a very broad range of indications, with fixed as well as moving targets; and
  • For research purposes, Penn Medicine will also deploy the Universal Monitoring Interface (UMI) and Adapt Analytics software. These software applications are used to monitor how much time is spent on and by the patient at different treatment stages. The aim of this research is to improve the workflow efficiency in order to optimize throughput. Ultimately, it will allow more patients, at Penn Medicine and elsewhere, to benefit from proton therapy treatment.

The current Penn Medicine upgrade exceeds $3 million USD, and IBA still has a general pipeline left of $7 million.

James Metz, M.D., chair of Penn Medicine Department of Radiation Oncology, commented, “The clinical application of proton therapy is a medical field in full evolution. At Penn Medicine, we believe in its potential and are fully committed to helping its realization, leveraging topnotch technology to make sure that as many eligible patients as possible can benefit from this radiation therapy modality, now and in the future.”

For more information: www.iba-worldwide.com

Related Content

One in three adults treated for cancer may experience side effects from treatment they wish they had known more about, according to a new survey published today in the Journal of Oncology Practice
News | Clinical Trials | November 21, 2019
November 21, 2019 — One in three adults treated for cancer may experience side effects from treatment they wish they
Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...